Newly Diagnosed mHSPC: First-Line Treatment Options
2025年1月2日 · Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) …
FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic …
2024年11月21日 · Darolutamide plus ADT significantly improved rPFS in mHSPC patients compared to placebo, with a hazard ratio of 0.54 and P< .0001. The ARANOTE trial showed …
Advancing Survival in mHSPC with New Standards - EMJ
2024年12月9日 · METASTATIC hormone-sensitive prostat e cancer (mHSPC) often begins asymptomatically but typically progresses to metastatic castration-resistant prostate cancer …
Darolutamide Plus ADT Shows Promise in Treating Metastatic …
2024年7月17日 · The nonsteroidal antiandrogen darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to improvements in radiological progression-free survival (rPFS) …
Newly diagnosed Diagnosed mHSPC: Goals of Therapy
2024年12月16日 · Evan Y. Yu, MD, discusses how the goals of therapy for a patient with newly- diagnosed metastatic hormone-sensitive prostate cancer are to control disease progression, …
Adding darolutamide to ADT extends rPFS in mHSPC - Urology …
2024年7月17日 · Darolutamide, which was developed in a collaboration between Bayer and Orion, is currently approved in the US for the treatment of patients with non-metastatic …
Bayer submits application in China for third indication of …
5 天之前 · Berlin, January 7, 2025 – Bayer has filed an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for marketing …
The Latest Research on mHSPC - UroToday
2024年8月28日 · The metastatic hormone-sensitive prostate cancer (mHSPC) disease space has seen the emergence of doublet and triplet therapy systemic treatment options, with current …
Systemic treatment of metastatic hormone-sensitive prostate …
2023年3月20日 · Survival of men with mHSPC has dramatically improved over recent years for the first time exceeding a median of >5 years by adding an ARSI to ADT + DOCE upfront for fit …
Darolutamide Plus ADT Beneficial in mHSPC Without Docetaxel
2024年9月20日 · Darolutamide plus androgen deprivation therapy (ADT) significantly improves radiographic progression-free survival (rPFS) among patients with metastatic hormone …